Pharmacokinetic Optimisation in the Treatment of Pneumocystis carinii Pneumonia
- 1 May 1993
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 24 (5) , 388-412
- https://doi.org/10.2165/00003088-199324050-00004
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Pharmacokinetic Justification of Antiprotozoal TherapyClinical Pharmacokinetics, 1991
- Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected MenThe Journal of Infectious Diseases, 1991
- Clindamycin and primaquine as primary treatment for mild and moderately severePneumocystis carinii pneumonia in patients with AIDSEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Treatment of Malaria - 1990Drugs, 1990
- Treatment of Experimental Pneumocystis carinii Pneumonia with Analogs of PentamidineThe Journal of Protozoology, 1989
- Trimetrexate for the Treatment ofPneumocystis cariniiPneumonia in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1987
- Pentamidine IsethionateDrugs, 1987
- Clinical Pharmacokinetics of Co-TrimazineClinical Pharmacokinetics, 1986
- Comparison of pentamidine isethionate andtrimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumoniaThe Journal of Pediatrics, 1978
- Pneumocystis carinii pneumonitis in children with malignanciesThe Journal of Pediatrics, 1973